![Restoration of Li+ pathways in the [010] direction during direct regeneration for spent LiFePO4](http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D5EE00641D)
.jpg)
European VC shop Sofinnova closes €165M biotech acceleration fund with support from Amgen, BMS and Pfizer Ventures
Sofinnova Partners on Tuesday announced the final close of its biotech acceleration fund Biovelocita II, which managed to raise 165 million euros ($180 million) through “substantial backing” from the likes of Amgen, Bristol Myers Squibb and Pfizer Ventures.
Sofinnova Partners on Tuesday announced the final close of its biotech acceleration fund Biovelocita II, which managed to raise 165 million euros ($180 million) through “substantial backing” from the likes of Amgen, Bristol Myers Squibb and Pfizer Ventures.
